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Abstract
Dendritic cells (DC) are increasingly prepared in vitro for use in immunotherapy trials. Mature DC
express high levels of surface molecules needed for T cell activation and are superior at antigen-
presentation than immature DC. Bacillus Calmette-Guerin (BCG) is one of several products known
to induce DC maturation, and interferon (IFN)-γ has been shown to enhance the activity of DC
stimulated with certain maturation factors. In this study, we investigated the use of IFN-γ in
combination with the powerful maturation agent, BCG. The treatment of immature DC with IFN-
γ plus BCG led to the upregulation of CD54, CD80, and CD86 in comparison with BCG treatment
alone. In MLR or recall immune responses, the addition of IFN-γ at the time of BCG-treatment did
not increase the number of antigen-specific T cells but enhanced the development of IFN-γ-
producing Th1 cells. In primary immune responses, on the other hand, BCG and IFN-γ co-treated
DC stimulated higher proportions of specific T cells as well as IFN-γ secretion by these T cells.
Thus the use of IFN-γ during BCG-induced DC maturation differentially affects the nature of recall
versus naïve antigen-specific T-cell responses. IFN-γ co-treatment with BCG was found to induce
IL-12 and, in some instances, inhibit IL-10 secretion by DC. These findings greatly enhance the
potential of BCG-matured dendritic cells for use in cancer immunotherapy.
Background
Dendritic cells (DC), the professional antigen presenting
cells of the immune system, are increasingly prepared in
vitro for use in the experimental immunotherapy of can-
cer. The production of DC with optimal immunostimula-
tory properties and their exploitation in cancer therapy
requires an understanding of the biology of these cells
during in vitro culture. Various protocols for the culture of
these cells have been established with the specific purpose
of human clinical use, and various advantages ascribed to
each [1–6]. Recent improvements include the use of
serum-free media [7,8], and the development of fully
closed purification and culture systems [5,6].
Maturation of DC is the process that converts immature
DC, which are phenotypically similar to skin Langerhans
cells, to mature antigen presenting cells that migrate to
lymph nodes. This process results in the loss of the pow-
erful antigen uptake capacity that characterizes immature
DC and in the upregulation of co-stimulatory molecule
expression and of various cytokines [9,10]. Known matu-
ration protocols are based on the environment that DC
are believed to encounter after or during exposure to anti-
gens. The best example of this approach is the use of
monocyte-conditioned media (MCM). MCM is generated
in vitro by culturing monocytes and then using the culture
supernatant fluid as a source of maturation factors. The
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major components in MCM responsible for maturation
are the pro-inflammatory cytokines interleukin-1 beta (IL-
1β), IL-6 and tumor necrosis factor alpha (TNF-α)[11].
Other maturation protocols include TNF-α either used
alone [12] or in combination with other factors like pros-
taglandin E2 (PGE2)[13] or vasoactive intestinal peptide
[14], poly-dIdC [15] bacterial lipopolysaccharide (LPS)
[16], as well as mycobacteria or components of mycobac-
teria, such as specific cell wall constituents [17–19].
Fully mature DC differ qualitatively from immature DC.
They express higher levels of MHC class I and class II anti-
gens, cellular adhesion molecules such as CD54, and of T
cell co-stimulatory molecules such as CD40, CD80 and
CD86 [12]. These changes increase their capacity to acti-
vate T-cells as they increase antigen density on the surface,
as well as the magnitude of the T cell activation signal
through the counterparts of the co-stimulatory molecules
on the T-cells, such as CD28. In addition, mature DC pro-
duce a variety of cytokines, which stimulate and direct the
T cell response. Two of these cytokines are interleukin-10
(IL-10) and IL-12. These cytokines have opposing effects
on the direction of the induced T cell response: IL-12
induces a Th1 type response [20,21] whereas IL-10 inhib-
its such response [22]. The former is particularly desirable
in cancer immunotherapy: a Th1 type response results in
the induction and differentiation of cytotoxic T lym-
phocytes (CTL), which constitute the effector arm of the
immune system and most effective in combating tumor
growth [23]. IL-12 also induces growth of natural killer
(NK) cells [24], and has anti-angiogenic activity [25], both
of which are effective anti-tumor weapons. Therefore, the
use of DC that produce IL-12 is, in theory, optimally
suited for use in the active immunotherapy of cancer.
BCG has an extensive history of use in cancer immuno-
therapy: intravesical administration of live BCG has
proven effective for the treatment of bladder cancer [26].
The effects of BCG administration are postulated to be via
the induction of an immune response that attacks cancer
cells. The specific role of BCG in this response is probably
that of a generalized inducer of immune reactivity, as well
as an adjuvant in the presentation of tumor antigens to
the immune system [27,28]. The use of BCG in active
immunotherapy using dendritic cells has the potential of
combining these effects with the established capacity of
BCG to induce dendritic cell maturation. Also, pharma-
ceutical-grade BCG is available commercially, which adds
the advantage of use in human clinical trials. BCG is a
powerful maturation agent for dendritic cells, with the
ability to up-regulate the maturation marker CD83 as well
as MHC molecules and the co-stimulatory molecules
CD80 and CD86, concomitant with a reduction in endo-
cytic capacity [17–19,29]. BCG-derived lipoarabinoman-
nan was found to increase in vitro production of IL-12, IL-
6 and TNF-α [30].
Recent reports demonstrated enhancement of IL-12 pro-
duction by dendritic cells that are matured using matura-
tion factors such as LPS and CD40 through the addition
of interferon-gamma (IFN-γ) [31,32]. Both LPS and CD40
have the capacity to induce the production of small
amounts of IL-12 during maturation in vitro [33], and it is
possible that the addition of IFN-γ merely enhances that
potential. It was therefore of interest to us to study the
combination of BCG and IFN-γ for dendritic cell matura-
tion, to determine whether the beneficial effects of this
cytokine extend to a maturation agent that has not been
reported to induce IL-12 secretion.
Methods
Reagents and cells
BCG (BCG-Tice®, Organon Teknika, Durham, NC), inacti-
vated in-house by heat and formalin-fixation, and IFN-γ
(Actimmune®, InterMune Pharmaceuticals, Brisbane, CA)
were used in the maturation of DC. Inactivated Influenza
A virus (Chemicon, Temecula, CA), Influenza M1 protein
from strain A/PR/8/34 (Virodynamics Corp., New York,
NY), and KLH (Sigma Chemical Co., St. Louis, MO), were
loaded into DC in experiments involving antigen-specific
responses, PMA (Sigma) and sterile, azide-free, low-endo-
toxin monoclonal anti-human CD3 antibody (BD
Pharmingen, San Diego, CA), rhIL-2 (Peprotech, Rocky
Hill, NJ) and rhIL-15 (Peprotech) were utilized in the
preparation of antigen-specific cells, and 3H-thymidine
(Perkin Elmer Life Sciences, Boston, MA) was used in
assays involving cell proliferation. For western blotting,
polyclonal anti-pY STAT1 antibodies were purchased
from UpState Biotechnology (Lake Placid NY). The anti-
STAT1α91 monoclonal antibody was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). The anti-α-
tubulin monoclonal antibody was purchased from Sigma
Chemical Co. (St. Louis, MO). Human peripheral blood
mononuclear cells (PBMC) were isolated from fresh leu-
kaphereses via density gradient centrifugation using Ficoll
(Sigma). The PBMC were cryopreserved in 90% serum
and 10% dimethyl sulfoxide (DMSO) until used. These
PBMC were used for DC culture and also for preparing T-
cells used in bioassays. Enriched T-cells were prepared
from allogeneic PBMC by negative depletion using anti-
HLA-DR monoclonal antibody-conjugated paramagnetic
beads (Dynal, Lake Success, NY).
DC culture
Previously frozen PBMC were thawed in warm AIM-V
medium (Life Technologies, Gaithersburg, MD), washed
once with PBS, and resuspended at 5–10 × 106 cells/ml in
Opti-MEM™ medium (Invitrogen Corp., Carlsbad, CA)
supplemented with 1% heat-inactivated pooled humanJournal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/7
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serum AB (Gemini BioProducts, Woodland, CA). Ten ml
of this cell suspension was dispensed into each T-75 cul-
ture flask and incubated for 1 h. After the incubation, non-
adherent cells were resuspended and aspirated out, fol-
lowed by stringent washing with cold PBS to remove
loosely adherent cells. Fifteen ml of serum-free X-VIVO-
15™ medium (BioWhittaker, Walkersville, MD) supple-
mented with 500 IU/ml each of rhGM-CSF (Leukine™,
Immunex, Seattle, WA) and rhIL-4 (R&D Systems, Minne-
apolis, MN, and alternatively Peprotech) was added to
each flask and the adherent cells (monocytes) cultured for
6 days which typically resulted in >90% CD11c+ HLA-DR+
"immature" DC that were >90% viable (determined by
trypan blue exclusion). For maturation, these DC were
treated with BCG or BCG plus IFN-γ for 24–48 h as
described in the experiments below.
Flow cytometry
Cell surface molecule expression was evaluated by stain-
ing DC with the following antibodies (BD Pharmingen):
FITC-labeled anti-CD80, anti-CD86, anti-Vβ17, PE-
labeled anti-CD54, PerCP-labeled anti-HLA-DR, or
CyChrome-labeled anti-CD8 and anti-CD4. Cells were
suspended in staining buffer (PBS containing 1% BSA and
0.01% sodium azide, pH 7.2) at 5 × 106 cells/ml, and 50
µl aliquots stained with individual antibodies, or with
combinations of antibodies. For intracellular staining, the
Cytofix/Cytoperm™ kit (BD Pharmingen) was utilized
with FITC-labeled anti-TNF-α and PE-labeled anti-IFN-γ,
anti-IL4 or anti-IL-2, following the manufacturer's instruc-
tions. To enable optimal detection, cytoplasmic cytokines
were allowed to accumulate by including GolgiPlug™ (BD
Pharmingen) in the last 6–16 hours of culture before
staining.
Mixed leukocyte reaction
Mixed leukocyte reaction (MLR) cultures were set up by
adding 2 × 105 enriched allogeneic T-cells to specific num-
bers of DC in triplicate wells of a 96-well microculture
plate. Five days later culture supernatants collected for
evaluating IFN-γ secretion by ELISA or the cultures were
pulsed with 3H-thymidine for an additional 24 h before
the cells were harvested onto glass fiber filters using a Fil-
terMate™ harvester (Packard, Meriden, CT) and the incor-
porated radioactivity quantified in a TopCount™
scintillation counter (Packard). For co-stimulatory mole-
cule blocking studies sterile, azide-free, and low-endo-
toxin monoclonal antibodies specific for CD54, CD80,
CD86, and an isotype control (BD Pharmingen) were
added to the DC at 1 µg/well for 1 h at the initiation of the
6 day culture, prior to the addition of T-cells.
Generation of antigen-specific T cell lines
Monocyte derived DC from normal donors were loaded
with KLH or inactivated Influenza A virus (30 – 40 µg/200
µl X-VIVO-15™ medium for 1 h, followed by 3–4 washes
with medium) and matured using BCG, with or without
IFN-γ for 18 to 24 hours. To stimulate KLH or Influenza A
specific T cells, PBMC were stimulated with the antigen
loaded autologous DC. The lines were cultured in AIM-V
media supplemented with 5% heat inactivated human AB
serum and given 20 U/mL recombinant human (rh) IL-2
and 5 ng/mL rhIL-15 every 2 – 3 days of culture as needed.
The KLH-specific primary cell lines were re-stimulated
every 12 to 14 days with KLH-loaded autologous DC.
These primary T cell lines were tested for antigen specifi-
city by proliferation assay and IFN-γ release after at least
three rounds of such in vitro stimulation.
Antigen-specific Proliferation Assay
To test for antigen specificity, unloaded or antigen-loaded
(Infuenza A or KLH) DC were irradiated (2000 cGy) and
distributed over the wells of a 96-well tissue culture plate
at 2 × 103 cells/well. KLH-specific T cells stimulated 10 –
14 days earlier, were titrated into the wells at ratios of
50:1, 25:1 and 12.5:1 T cells to DC. Assays were per-
formed using AIMV + 5% heat inactivated human AB
serum. After 44 ± 4 hours 100 µl of media was removed
for ELISA purposes, 1 µCi of 3H-Thymidine was added per
well, and the cells were incubated for an additional 18
hours. Cells were thereafter harvested and 3H-thymidine
incorporation was measured using a FilterMate™ (Pack-
ard) cell harvester and the incorporated radioactivity
quantified in a TopCount™ scintillation counter
(Packard).
ELISA
Cytokines in supernatants from DC cultures with different
treatments or co-cultures with T-cells were quantified by
ELISA. Anti-IL-10, anti-IL-12, and anti-IFN-γ antibody
pairs and recombinant cytokine standards were purchased
from BD Pharmingen. The manufacturer's recommended
ELISA protocol were followed to determine cytokine con-
centrations in the supernatants. The sensitivity of each
ELISA was at least 15 pg/ml.
Results
Effects of IFN-γ on BCG-induced maturation of DC
We had previously found that DC respond to killed BCG
mycobacteria with increased expression of MHC class I
and class II molecules, CD54, CD80 and CD86, and
CD83. These phenotypic consequences of maturation
induced by BCG have also been described by others, and
are similar to those obtained using other maturation fac-
tors such as LPS or monocyte-conditioned media. To
investigate the consequences of IFN-γ addition to BCG-
induced DC maturation, we first tested the expression of
maturation-associated markers. Dendritic cells matured
for 48 h with BCG alone, or in combination with various
concentrations of IFN-γ were analyzed by flow cytometryJournal of Translational Medicine 2003, 1 http://www.translational-medicine.com/content/1/1/7
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IFN-γ in combination with BCG stimulates enhanced DC surface expression of CD54, CD80, and CD86 Figure 1
IFN-γ in combination with BCG stimulates enhanced DC surface expression of CD54, CD80, and CD86 DC, 
derived from 6-day monocyte cultures with GM-CSF and IL-4, were left untreated, matured with 4.1 × 105 CFU/ml of BCG 
alone, or in combination with various concentrations of IFN-γ for an additional 2 days in the presence of GM-CSF and IL-4. 
Cells were harvested and analyzed by flow cytometry for CD54, CD80, and CD86 expression. DC-gated (based on light scat-
ter properties) data are shown (from a representative experiment out of three similar experiments). Isotype control staining is 
overlaid and shown by the light gray curve. Percent positive cells are shown in each panel and mean fluorescence intensity indi-
cated within parentheses.
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for CD54, CD80, and CD86 expression. Figure 1 shows
the upregulation of DC cell surface molecules in response
to a 48 h exposure to increasing amounts of IFN-γ added
to a fixed concentration of inactivated BCG. As expected,
compared to immature DC a larger percentage of BCG-
matured DC expressed co-stimulatory molecules, and this
percentage was not affected by IFN-γ co-treatment. In con-
trast, the level of expression of these molecules on the
cells was upregulated by IFN-γ. At the highest dose tested
(1000 U/ml), there was an approximately 2-fold increase
in CD54 and CD80 expression, and a 3-fold increase in
CD86 expression, as measured by mean fluorescence
intensity (MFI). The expression levels of CD83, MHC
class-I, and MHC class-II were not different between BCG
alone versus BCG and IFN-γ co-treatment, but higher than
that of immature DC by at least 2-fold (data not shown).
To investigate whether this potentiating effect of IFN-γ on
BCG-induced DC maturation was restricted to surface
molecule expression alone, we evaluated the production
of TNF-α. DC were matured for 36 h as above and the pro-
portion of TNF-α-producing DC was determined by intra-
cellular cytokine staining. As indicated in Figure 2, IFN-γ
induced over a 3-fold increase in the proportion of BCG-
matured DC producing TNF-α. Furthermore, the TNF-α
levels on a per-cell-basis were noticeably higher in DC
matured with the combination of BCG plus IFN-γ com-
pared to those DC matured with BCG alone. These initial
results suggested that IFN-γ enhances BCG-induced DC
maturation.
Addition of IFN-γ during BCG-induced DC maturation 
changes the outcome of DC-T cell interactions
The observed increase in co-stimulatory molecules and
TNF-α production suggested the potential for enhanced T
cell stimulation by DC that were matured using BCG and
IFN-γ as opposed to those matured with BCG alone. We
tested this hypothesis by performing a mixed lymphocyte
reaction. Immature DC, or DC matured with BCG alone
or BCG plus IFN-γ for 24 h, were cultured with enriched
allogeneic T cells. As shown in Figure 3A, the DC matured
in the presence of BCG alone or BCG plus IFN-γ were both
found to induce stronger T cell proliferative responses
than immature DC, while there was no significant differ-
ence between DC matured in either manner. On the other
hand, IFN-γ co-treated DC induced significantly greater
IFN-γ secretion by T-cells responding to alloantigenic
stimuli, especially at lower T-cell:DC ratios, than did DC
matured in the absence of IFN-γ (Figure 3B). These data
provided an initial indication that IFN-γ addition during
BCG-induced maturation modulates a change in the qual-
ity but not the quantity of the ensuing T-cell response.
IFN-γ treatment in combination with BCG induces TNF-α in a higher percentage of dendritic cells than treatment with BCG  alone Figure 2
IFN-γ treatment in combination with BCG induces TNF-α in a higher percentage of dendritic cells than treat-
ment with BCG alone DC were treated with 1.6 × 106 CFU/ml of BCG, with or without 1000 U/ml IFN-γ, or left untreated 
(immature). Twenty hours later GolgiPlug™ was added to inhibit cytokine secretion and the cells were cultured for an addi-
tional 16 h prior to intracellular staining with anti-TNF-α-FITC and extracellular staining with anti-HLA-DR, DP, DQ-PerCP. 
Data shown here are from a representative experiment out of four similar experiments.
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Addition of IFN-γ during BCG-induced DC maturation 
differentially affects the nature of recall versus naïve 
antigen-specific T-cell responses
Next, we investigated whether the qualitative immunopo-
tentiating effect of IFN-γ on BCG-induced DC maturation
also applies to antigen-specific T cell responses. The recall
T-cell response to influenza was used as the model system
to address this question. DC from an HLA-A2.1+ donor
were loaded with inactivated influenza-A virus or KLH,
followed by maturation with BCG, in the presence or
absence of IFN-γ. After maturation the DC were washed
and mixed with autologous PBMC at a 10:1 (PBMC: DC)
ratio. Seven-to-eight days later the resulting cell lines were
counted and analyzed by flow cytometry for the percent-
age of Vβ17+CD8+ T cells, which are a population of T-
cells that react specifically with the immunodominant
HLA-A2*01-restricted matrix (M1) protein peptide [34].
Figure 4A shows the data expressed as a percentage of the
response seen using Influenza A-pulsed immature DC
("percent of control"). We found that both maturation
conditions led to the expansion of Vβ17+ T-cells to the
same degree, but were both significantly higher than that
induced by immature DC. From this it is apparent that
memory T-cells will expand in response to mature anti-
gen-loaded DC, and the level of expansion was not
dependent on the presence of IFN-γ during maturation.
Our next question was whether there were qualitative
changes resulting from the change in maturation condi-
tions. The influenza A virus-stimulated T cells generated
above were re-stimulated for 40 h with Influenza M1 pro-
tein-loaded DC and evaluated for IFN-γ production by
intracellular cytokine staining. As shown in Figure 4B,
only 6% of the cells that were expanded using DC
matured with BCG alone produced IFN-γ. On the other
hand a 4-fold higher proportion (25%) of the cells that
were expanded using DC matured with BCG and IFN-γ
produced this cytokine. Using similar assays we were una-
ble to detect production of IL-4, IL-5 or IL-10 by these T-
cells (data not shown). These results mirrored our find-
ings from the earlier MLR experiments, that the addition
of IFN-γ during DC maturation modulated the qualitative
response of T-cells.
To assess the capacity of DC to induce responses in naïve
T-cells, we stimulated PBMC three times with autologous
DC loaded with KLH and matured with BCG, in the pres-
ence or absence of IFN-γ. The resulting T cell lines were
tested for antigen specificity by standard proliferation
assay. Only those lines that were generated using DC
matured with BCG and IFN-γ proliferated in response to
KLH, and not to the control antigen Influenza-A or
unloaded DC (Figure 5A). When these lines were non-spe-
cifically stimulated with anti-CD3 and PMA, the T-cells
that were expanded using DC matured with BCG and IFN-
γ produced IFN-γ whereas those expanded using DC
matured with BCG alone did not. No significant differ-
ences were seen on IL-2 and IL-4 production (Figure 5B).
IFN-γ co-treatment with BCG induces IL-12 and inhibits 
BCG-induced IL-10 secretion by DC
Given the above findings of enhanced capacity of DC
matured with BCG plus IFN-γ to induce Th1 cells under
several experimental conditions, we sought to examine
next whether this effect of IFN-γ was mediated via modu-
lation of the Th1:Th2 cytokine balance among DC-pro-
duced cytokines. Culture supernatants from DC matured
for 24 h using BCG alone, or in combination with
IFN-γ treatment affects the quality but not quantity of the all- ogeneic T cell MLR response stimulated by BCG matured  DC Figure 3
IFN-γ treatment affects the quality but not quantity 
of the allogeneic T cell MLR response stimulated by 
BCG matured DC DC were treated with 4.1 × 105 CFU/
ml of BCG alone, BCG plus 1000 U/ml IFN-γ or left 
untreated (immature) for 24 h prior to mixed leukocyte cul-
ture. Varying numbers of DC were added to 2 × 105 
enriched T cells in triplicate wells of a 96-well microculture 
plate and cultured for 5 days. The cells were pulsed with 3H-
thymidine for an additional 24 h before harvesting and quan-
titation of incorporated radioactivity in a scintillation counter 
(A). Immediately preceding the 3H-thymidine pulse, culture 
supernatants were collected for evaluating IFN-γ secretion 
(B). Results shown in each panel are from a representative 
experiment out of three similar experiments.
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IFN-γ treatment in combination with BCG or BCG alone induces similar proportions of antigen-specific Vβ17+ T cells in recall  responses, but which differ in IFN-γ producing ability Figure 4
IFN-γ treatment in combination with BCG or BCG alone induces similar proportions of antigen-specific Vβ17+ 
T cells in recall responses, but which differ in IFN-γ producing ability DC were loaded with inactivated Influenza A 
virus or control protein (KLH) by pulsing with these proteins for 1 h followed by 2 hours of incubation before maturation with 
BCG (1.6 × 106 CFU/ml), BCG and IFN-γ (1000 U/ml), or left untreated (immature). After 20 hours of maturation, the DC 
were washed and autologous PBMC were added at a 10:1 (PBMC:DC) ratio in AIM-V media containing IL-2 and IL-15. Seven or 
eight days later the resulting cell lines were counted, analyzed for the percentage of Vβ17+CD8+ expression on T cells by flow 
cytometry, and the results calculated as a percent of the response seen using Influenza A-pulsed immature DC as the control 
(A). The influenza A virus-specific Vβ17+CD8+ T cells were re-stimulated for 40 h (including addition of GolgiPlug™ in the last 
16 h) with immature or BCG ± IFN-γ matured DC loaded with Influenza M1 protein and evaluated for intracellular IFN-γ (B). 
Data in panel A are combined from three separate experiments and data in panel B are from one representative experiment 
out of four similar experiments.
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increasing concentrations of IFN-γ, were tested for the
presence of IL-12 and IL-10 by ELISA. In the presence of
IFN-γ, production of IL-12 p70 was substantially
increased upwards of several ng/ml while the production
of IL-10 was reduced (Figure 6A). The reduction of IL-10
production, though not seen in samples from all donors,
was confirmed by the results of several experiments repre-
sented in Figure 6B. DC were cultured with various con-
centrations of BCG, or IFN-γ in combination with a fixed
concentration of BCG, or IFN-γ alone. It was found that
while BCG induced IL-10 secretion in a dose-dependent
manner, IFN-γ co-treatment inhibited its production. IFN-
γ alone produced no effect on IL-10 secretion. Apparently,
the addition of IFN-γ reverses the pattern of cytokine pro-
duction by DC in response to BCG-induced maturation,
to a mixture that is more favorable to induction of a Th1
response.
DC matured with BCG alone or in combination with IFN-γ 
stimulate T-cells via the same co-stimulatory molecules
Another level of signal modulation by IFN-γ during BCG-
induced maturation is possibly via the induction of
BCG and IFN-γ matured DC induce primary CD4+ Th1-type  T cell responses as opposed to BCG matured or immature  DC Figure 5
BCG and IFN-γ matured DC induce primary CD4+ 
Th1-type T cell responses as opposed to BCG 
matured or immature DC PBMC were stimulated with 
KLH-loaded DC matured with either BCG alone (1.6 × 106 
CFU/ml) or BCG and IFN-γ (1000 U/ml). Every 10–14 days 
the cell lines were re-stimulated with the same DC used in 
the initial in vitro stimulation. After 3–5 rounds of such stimu-
lation, the resulting cells were analyzed for KLH-specific pro-
liferation in a 3H-thymidine incorporation assay as described 
in Materials and Methods (A). The KLH-specific T cells were 
non-specifically stimulated with anti-CD3 and PMA for 8 h, 
including GolgiPlug™ for last 6 hours. Subsequently the cells 
were stained for intracellular IFN-γ, IL-4 or IL-2 (B). The data 
are from one representative experiment out of four similar 
experiments.
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The addition of IFN-γ during DC maturation with BCG  induces secretion of IL-12 and suppresses IL-10 production Figure 6
The addition of IFN-γ during DC maturation with 
BCG induces secretion of IL-12 and suppresses IL-10 
production IL-10 and IL-12 p70 cytokine were quantified in 
DC culture supernatants by ELISA after 24 hour maturation 
with BCG (1.6 × 106 CFU/ml) in the presence or absence of 
IFN-γ (1000 U/ml). Data shown represent the mean ± SD of 
IL-10 and IL-12 concentrations from four experiments (A). 
Increasing concentrations of BCG induces IL-10 secretion by 
DC in a dose dependent manner (in some donors) that is 
suppressed by the addition of IFN-γ. Data shown represent 
the mean ± SD of IL-10 concentrations obtained from three 
separate but identical experiments (B).
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additional co-stimulatory cell surface molecules that, in
turn, mediate the potentiation of the ensuing immune
responses by these DC. To address this, MLR cultures were
set up as earlier, and certain co-stimulatory molecules, or
a combinations of them, were blocked using specific anti-
bodies. Immature or matured DC were exposed to anti-
CD54, anti-CD80, anti-CD86, or isotype-matched control
blocking antibodies for 1 hour prior to addition of T-cells.
Proliferation (Figure 7A) and IFN-γ secretion (Figure 7B)
were measured. Blocking CD54, CD80, and CD86
together abrogated proliferation by over 95%, independ-
ent of the type of DC maturation protocol used. Similarly,
blocking these molecules inhibited 75% of the IFN-γ
secreted, indicating that the same co-stimulatory mole-
cules may be responsible for T cell activation. This data,
however, does not exclude the induction or upregulation
of new co-stimulatory molecules. As expected, there was a
reduction of IFN-γ production by the T cells in the pres-
ence of anti-IL-12 antibodies (Figure 7B), confirming that
IL-12 modulated the qualitative responses T cells in this
system.
Discussion
The interaction between dendritic cells and T cells is gov-
erned by many factors, all of which are subject to regula-
tion [35]. These factors include the availability of
antigenic peptides associated with MHC molecules, the
density of these MHC molecules on the cell surface and
the relative occupation of these molecules with antigenic
peptides. Other factors include the expression, density,
and balance of the co-stimulatory molecules such as
CD80 and CD86 and their levels of expression relative to
negative stimulatory molecules like CTLA-4 and FasL
[10,35–37]. In addition to these cell-bound factors, the
interaction is further governed by soluble factors that
include cytokines and chemokines. Active immuno-
therapy for cancer generally requires the breaking of toler-
ance to self-antigens. The minimal requirements for
accomplishing this are not known, but data from animal
experiments support the notion that high levels of antigen
density together with the appropriate co-stimulatory mol-
ecules and cytokines like IL-12 may be required [10,38–
40]. This paper describes a combination of maturation
factors for human DC which are compatible with clinical
protocols and which accomplish all of the above. Matura-
tion with BCG and IFN-γ increases MHC expression and
the expression of CD80 and CD86, and simultaneously
induces the production of IL-12. This induction of IL-12
p70 secretion is remarkable since maturation with BCG
alone is not associated with significant IL-12 production,
which could suggest that the use of BCG as a maturation
agent predisposes the DC to induce primarily Th2 like
responses. Our data show that the addition of IFN-γ to
BCG results in the production of high levels of IL-12, thus
creating the potential for strong Th1 type responses.
Besides this qualitative change, the addition of IFN-γ also
has quantitative aspects. It up-regulates the expression of
cell surface molecules that are involved in DC-T cell inter-
actions, and increases the production of other cytokines
like TNF-α. In our investigations into the effects of these
changes on the outcome of in vitro T cell activation we
found functionally distinct results. When using MLR or
recall responses and looking at cell proliferation, we
found that DC that are matured with BCG are equivalent
to those matured with BCG and IFN-γ. However, in both
of these cases, we also found that the responding cells had
T cell stimulation by DC matured with BCG alone or in com- bination with IFN-γ is mediated via identical co-stimulatory  molecules Figure 7
T cell stimulation by DC matured with BCG alone or 
in combination with IFN-γ is mediated via identical 
co-stimulatory molecules DC were treated with 4.1 × 
105 CFU/ml of BCG alone, BCG plus 1000 U/ml IFN-γ or left 
untreated (immature) for 24 h. The DC were harvested, 
washed, and placed in mixed leukocyte culture with alloge-
neic T cells at 1:100 ratio in triplicate wells of a microculture 
plate. Blocking antibodies were added to the DC at 1 µg/well 
for 1 h prior to the addition of T cells. Five days later culture 
supernatants collected for evaluating IFN-γ secretion by 
ELISA (B). The cells were pulsed with 3H-thymidine for an 
additional 24 h cells before harvest and quantification of 
incorporated radioactivity in a scintillation counter (A). 
Results shown in each panel are from one of two identical 
experiments.
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a greater propensity to produce the Th1 cytokine IFN-γ, if
IFN-γ was present during DC maturation with BCG. This
finding is in line with the well established IL-12 – IFN-γ
axis, and supports the notion that T cell activation as
measured by proliferation is independent of directional
instruction of the T cell response towards Th1. [41,42].
Dendritic cells are required for the induction of primary T
cell responses, both in vivo and in vitro [10,43–46]. We
have attempted to induce primary responses against KLH,
and were unsuccessful when we used DC matured with
BCG alone. In contrast, we were successful in generating
such responses when using DC matured with both BCG
and IFN-γ. This suggests that some of the properties
acquired by the DC through the addition of IFN-γ during
maturation better equip DC to stimulate naive T cells.
We have attempted to address the relative contribution of
known co-stimulatory molecules to one of the systems in
which we can measure both T cell proliferation and IFN-γ
production by the T cells, namely the mixed lymphocyte
reaction. A combination of antibodies to CD54, CD80
and CD86 almost completely abolished T cell activation,
irrespective of how the DC were matured and which read-
out system was chosen to measure activation. This sug-
gests that the addition of IFN-γ during maturation has not
changed the basic requirements for the DC-T cell
interaction, and that CD54, CD80 and CD86 are required.
One major result of the addition of IFN-γ is the stimula-
tion of IL-12 p70 and in some cases, reduction of IL-10,
secreted by the DC. We have tested whether IL-12 is
responsible for the increased levels of IFN-γ production by
the responding cells in the MLR, and indeed observed a
reduction of IFN-γ production by the T cells in the pres-
ence of anti-IL-12 antibodies if the DC were matured in
the presence of IFN-γ. The fact that IFN-γ levels were not
completely abolished by this treatment suggests that other
factors could be responsible for the induction of IFN-γ
secretion by T cells. These factors could include
chemokines such as IP-10 [47,48]. Recent reports have
illuminated the induction of IP-10 through TLR-4
agonists. BCG primarily acts through TLR-4 [19,49] and
thus is likely to induce the production of IP-10. This will
be the subject of future studies.
In our in vitro system, DC matured with BCG alone in
serum-free media were unable to induce primary T cell
responses against KLH. This finding is in contrast with
observations made by others that demonstrated the
induction of IL-12 using BCG-matured DC [17]. It is
important to note here that the literature describes many
methods of generating DC, including the use of different
media, different media additives including human or ani-
mal plasma or serum, and different concentrations of
cytokines and BCG [17,50]. We have observed functional
differences at the level of expressions of co-stimulatory
molecules or cytokines between DC that were generated
using such different conditions, and it is possible that
such differences or others that we have not yet identified
could be the basis for the different success rates of the
induction of primary responses in vitro. Regardless, we
find that the capacity to induce such responses is recov-
ered when IFN-γ is added during maturation. A recent
publication describes that full maturation of monocyte
derived DC requires 4 days of exposure to TNF-α [51]. In
our studies here we only exposed the DC to maturation
stimuli for 18–24 hours, and full functional maturation
with BCG may therefore require the presence of IFN-γ.
Conclusions
The use of different maturation factors is only one way by
which the quality of DC for active immunotherapy can be
influenced or improved. In this study, we discovered that
the addition of IFN-γ during BCG-induced DC maturation
induces IL-12 and, in some instances, inhibits IL-10 secre-
tion. Such treatment also differentially affects the nature
of recall versus naïve antigen-specific T-cell responses. We
have devised a protocol that uses materials compatible
with clinical use, and that generates highly potent DC
which confer Th1-like characteristics onto the responding
T cell population. These findings greatly enhance the
potential of BCG-matured dendritic cells for use in cancer
immunotherapy.
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